API | iratumumab

iratumumab Report issue

Biologics mAb Experimental

AACT ChEMBL MeSH

Active Ingredient History

NOW

Iratumumab is a human monoclonal antibody used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
iratumumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Tumor necrosis factor receptor superfamily member 8 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

5f11 monoclonal antibody | iratumumab | mdx-060 | mdx-060 monoclonal antibody | mdx060 monoclonal antibody

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Hodgkin Disease (Phase 2)

Lymphoma (Phase 1/Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 3
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue